JP2011525191A - 免疫応答を誘発するための組成物、方法およびキット - Google Patents

免疫応答を誘発するための組成物、方法およびキット Download PDF

Info

Publication number
JP2011525191A
JP2011525191A JP2011514851A JP2011514851A JP2011525191A JP 2011525191 A JP2011525191 A JP 2011525191A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011514851 A JP2011514851 A JP 2011514851A JP 2011525191 A JP2011525191 A JP 2011525191A
Authority
JP
Japan
Prior art keywords
antigen
cmv
cell
cells
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011514851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011525191A5 (enExample
Inventor
サンプソン，ジヨン・エイチ
ミツチエル，デユアン・エイ
Original Assignee
デユーク・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デユーク・ユニバーシテイ filed Critical デユーク・ユニバーシテイ
Publication of JP2011525191A publication Critical patent/JP2011525191A/ja
Publication of JP2011525191A5 publication Critical patent/JP2011525191A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2011514851A 2008-06-20 2009-06-19 免疫応答を誘発するための組成物、方法およびキット Pending JP2011525191A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7458208P 2008-06-20 2008-06-20
US61/074,582 2008-06-20
PCT/US2009/047987 WO2009155535A2 (en) 2008-06-20 2009-06-19 Compositions, methods and kits for eliciting an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015016782A Division JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット

Publications (2)

Publication Number Publication Date
JP2011525191A true JP2011525191A (ja) 2011-09-15
JP2011525191A5 JP2011525191A5 (enExample) 2012-08-09

Family

ID=41434717

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011514851A Pending JP2011525191A (ja) 2008-06-20 2009-06-19 免疫応答を誘発するための組成物、方法およびキット
JP2015016782A Pending JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット
JP2016249706A Active JP6342982B2 (ja) 2008-06-20 2016-12-22 免疫応答を誘発するための組成物、方法およびキット

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015016782A Pending JP2015134767A (ja) 2008-06-20 2015-01-30 免疫応答を誘発するための組成物、方法およびキット
JP2016249706A Active JP6342982B2 (ja) 2008-06-20 2016-12-22 免疫応答を誘発するための組成物、方法およびキット

Country Status (8)

Country Link
US (12) US8425898B2 (enExample)
EP (4) EP2303319B1 (enExample)
JP (3) JP2011525191A (enExample)
CN (1) CN102123732A (enExample)
AU (1) AU2009259923B2 (enExample)
CA (1) CA2728739C (enExample)
DK (1) DK3156069T3 (enExample)
WO (1) WO2009155535A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523824A (ja) * 2010-04-06 2013-06-17 ジョン ダブリュ． ホラデイ、 癌を治療する方法
JP2015536937A (ja) * 2012-10-30 2015-12-24 レッドヴァックス・ゲーエムベーハー ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
JP2019535665A (ja) * 2016-10-21 2019-12-12 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
WO2021206104A1 (ja) * 2020-04-08 2021-10-14 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
JP2022547298A (ja) * 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
JP2024506550A (ja) * 2021-01-29 2024-02-14 ティーヘルパー・アーエス 治療剤及び診断剤並びにその使用

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
EP2303319B1 (en) * 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US10369204B2 (en) 2008-10-02 2019-08-06 Dako Denmark A/S Molecular vaccines for infectious disease
JP6148666B2 (ja) * 2011-04-15 2017-06-14 セシリア ノークレール サイトメガロウイルス（ｃｍｖ）の遺伝子変異体
CN102363818B (zh) * 2011-06-28 2013-01-02 同昕生物技术（北京）有限公司 同时检测人ebv、bkv和 cmv的三重实时荧光定量pcr方法及试剂盒
EP2956557B1 (en) * 2013-02-14 2018-07-11 The J. David Gladstone Institutes Compositions and methods of use thereof for identifying anti-viral agents
US9950056B2 (en) 2013-09-24 2018-04-24 Duke University Compositions, methods and kits for eliciting an immune response
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US9974848B2 (en) 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines
US10078076B2 (en) 2013-11-26 2018-09-18 Duke University Immune monitoring to predict and prevent infection
SG11201703406YA (en) 2014-11-05 2017-05-30 Sloan Kettering Inst Cancer Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US20180133327A1 (en) 2015-03-16 2018-05-17 Amal Therapeutics Sa Cell Penetrating Peptides and Complexes Comprising the Same
CN107667178A (zh) * 2015-03-26 2018-02-06 休斯敦大学系统 细胞的整合功能和分子概况
EP3313419B1 (en) 2015-06-26 2020-08-19 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
MA46316A (fr) 2015-10-22 2021-03-24 Modernatx Inc Vaccin contre le cytomégalovirus humain
WO2017096247A1 (en) * 2015-12-04 2017-06-08 Mayo Foundation For Medical Education And Research Methods and vaccines for inducing immune responses to multiple different mhc molecules
WO2017127755A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CA3010236A1 (en) 2016-01-20 2017-07-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
RU2769314C1 (ru) 2016-03-16 2022-03-30 Амаль Терапьютикс Са Комбинация модулятора иммунных контрольных точек и комплекса, содержащего проникающий в клетку пептид, карго-молекулу и пептидный агонист tlr, для применения в медицине
HUE067838T2 (hu) 2016-09-21 2024-11-28 Amal Therapeutics Sa Egy sejtpenetráló peptidet, egy multiepitópot és egy TLR peptidagonistát tartalmazó fúzió rák kezelésére
JP2019530449A (ja) 2016-09-23 2019-10-24 メモリアル スローン ケタリング キャンサー センター 幹細胞様メモリーｔ細胞の生成および養子免疫療法における使用
JP7098615B2 (ja) 2016-12-05 2022-07-11 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
JP2021502355A (ja) * 2017-11-06 2021-01-28 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ 既存の微生物免疫を利用した癌処置
EP3747459A4 (en) 2018-02-02 2021-12-01 SL Vaxigen, Inc. NEW IMMUNOADJUVANT VACCINE
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3142110A1 (en) * 2019-05-31 2020-12-03 Variation Biotechnologies Inc. Immunotherapeutic compositions for treatment of glioblastoma multiforme
US11872288B2 (en) * 2020-05-22 2024-01-16 Philogen S.P.A. TNF-alpha immunoconjugate therapy for the treatment of brain tumors
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
EP4192494A4 (en) * 2020-08-06 2024-11-13 La Jolla Institute for Immunology Methods for treating and preventing cytomegalovirus infection
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022192323A1 (en) * 2021-03-09 2022-09-15 Board Of Regents, The University Of Texas System Low intensity ultrasound combination cancer therapies
CN117257925B (zh) * 2023-09-20 2024-05-28 青岛大学 基于人巨细胞病毒编码即刻早期蛋白ie的疫苗、其制备方法和应用
CN117169518B (zh) * 2023-11-03 2024-01-19 赛德特(北京)生物工程有限公司 T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519181A (ja) * 1997-10-14 2001-10-23 シティ・オブ・ホープ ヒトサイトメガロウィルスの免疫反応性ペプチドｃｔｌエピトープ
JP2003528887A (ja) * 2000-03-27 2003-09-30 シティ・オブ・ホープ ヒトサイトメガロウイルスの免疫ー反応性ペプチドｃｔｌエピトープ

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US6207161B1 (en) 1986-07-16 2001-03-27 City Of Hope Induction of cytolytic T-lymphocytes with cytomegalovirus polypeptides
US4906564A (en) 1987-03-13 1990-03-06 The United States Of America As Represented By The Secretary Of The Army Antigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigens
ATE194657T1 (de) 1990-09-25 2000-07-15 Cantab Pharma Res Bei einer transkomplementenden zellinie erzeugter defektiver virenimpfstoff
WO1994016730A1 (en) * 1993-01-28 1994-08-04 Sandoz Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
WO1994021807A2 (en) 1993-03-19 1994-09-29 Cantab Pharmaceuticals Research Limited Defective mutant non-retroviral virus (e.g. hsv) as vaccine
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6074645A (en) * 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6503503B1 (en) 1997-05-13 2003-01-07 Duke University Allogeneic cellular vaccine
US6013258A (en) 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
IL125608A0 (en) 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
WO2000011950A1 (en) 1998-08-31 2000-03-09 Oregon Health Science University Prevention of cell migration initiation with cmv us28 receptor antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6350451B1 (en) 1999-06-25 2002-02-26 The Board Of Trustees Of The University Of Arkansas Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
AU2001240109A1 (en) 2000-03-07 2001-09-17 U.S. Army Medical Research Institute Of Infectious Diseases Dna vaccines against poxviruses
EP1655305A3 (en) 2000-03-21 2006-09-13 Genzyme Corporation Therapeutic anti-cytomegalovirus compounds
EP1146119A1 (en) * 2000-04-12 2001-10-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for obtaining specific T-lymphocytes, and for identifying unknown epitopes
AU2001288682A1 (en) * 2000-08-30 2002-03-13 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
ES2386884T3 (es) 2000-11-01 2012-09-04 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Vectores de expresión capaces de inducir respuesta inmunomejorada y métodos para usarlos
AU2002242085A1 (en) 2001-02-02 2002-08-19 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
AUPR395801A0 (en) 2001-03-26 2001-04-26 Austin Research Institute, The Antibodies against cancer
AUPR593101A0 (en) 2001-06-26 2001-07-19 Council Of The Queensland Institute Of Medical Research, The Cytomegalovirus t cell epitopes
US8530151B2 (en) 2002-09-03 2013-09-10 Charles S. Cobbs Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
WO2004027036A2 (en) 2002-09-19 2004-04-01 Johns Hopkins University School Of Medicine Cancer immunotherapy with a viral antigen-defined, immunomodulator-secreting cell vaccine
ES2282355T3 (es) 2002-10-11 2007-10-16 Sentoclone Ab Inmunoterapia de cancer.
WO2004053095A2 (en) 2002-12-10 2004-06-24 Merix Bioscience, Inc. In situ maturation of dendritic cells
DK2311848T3 (da) * 2002-12-23 2013-10-14 Vical Inc Kodon-optimerede polynukleotidbaserede vacciner mod human cytomegalovirus-infektion
WO2004093905A1 (en) * 2003-04-16 2004-11-04 City Of Hope Human cytomegalovirus antigens expressed in mva and methods of use
US20050232933A1 (en) * 2003-09-30 2005-10-20 Zaia John A CMV-IE1 peptides and method of use
WO2006056027A1 (en) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
US20100111992A1 (en) * 2006-05-01 2010-05-06 The Regents Of The University Of California Cytomegalovirus peptides and methods of use thereof
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US8435510B2 (en) * 2007-08-08 2013-05-07 Sutter West Bay Hospitals Platelet derived growth factor receptor supports cytomegalovirus infectivity
EP2303319B1 (en) * 2008-06-20 2016-10-05 Duke University Compositions, methods and kits for eliciting an immune response
CN102076354A (zh) 2008-07-03 2011-05-25 杜克大学 用于引发免疫应答的组合物和方法
US9974848B2 (en) * 2013-11-14 2018-05-22 Duke University Tetanus toxoid and CCL3 improve DC vaccines

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519181A (ja) * 1997-10-14 2001-10-23 シティ・オブ・ホープ ヒトサイトメガロウィルスの免疫反応性ペプチドｃｔｌエピトープ
JP2003528887A (ja) * 2000-03-27 2003-09-30 シティ・オブ・ホープ ヒトサイトメガロウイルスの免疫ー反応性ペプチドｃｔｌエピトープ

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN7013004237; Ｃｌｉｎ　Ｅｘｐ　Ｉｍｍｕｎｏｌ，　２００５，　１３９（３），　ｐ．４５８-６７ *
JPN7013004238; Ｂｒ　Ｊ　Ｈａｅｍａｔｏｌ，　２００３，　１２１（３），　ｐ．４２８-３８ *
JPN7013004239; Ｃａｎｃｅｒ　Ｒｅｓ，　２００２，　６２（１２），　ｐ．３３４７-５０ *
JPN7013004240; Ｃａｎｃｅｒ　Ｒｅｓ，　２００８　Ｆｅｂ，　６８（３），　ｐ．７２４-３０ *
JPN7013004241; Ｖａｃｃｉｎｅ，　２００７，　２５（６），　ｐ．１１３２-４１ *
JPN7013004242; Ｍｅｔｈｏｄｓ，　１９９９，　１９（１），　ｐ．１１４-２０ *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523824A (ja) * 2010-04-06 2013-06-17 ジョン ダブリュ． ホラデイ、 癌を治療する方法
US9107878B2 (en) 2010-04-06 2015-08-18 Exocyte Therapeutics Pte, Ltd Methods of treating cancer
JP2017002054A (ja) * 2010-04-06 2017-01-05 エクソサイト セラピューティクス ピーティイー リミテッド 癌を治療する方法
JP2015536937A (ja) * 2012-10-30 2015-12-24 レッドヴァックス・ゲーエムベーハー ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
JP2019535665A (ja) * 2016-10-21 2019-12-12 モデルナティーエックス， インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2022024088A (ja) * 2016-10-21 2022-02-08 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2023106473A (ja) * 2016-10-21 2023-08-01 モデルナティエックス インコーポレイテッド ヒトサイトメガロウイルスワクチン
JP2022547298A (ja) * 2019-09-09 2022-11-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫療法組成物
WO2021206104A1 (ja) * 2020-04-08 2021-10-14 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
JP2024506550A (ja) * 2021-01-29 2024-02-14 ティーヘルパー・アーエス 治療剤及び診断剤並びにその使用

Also Published As

Publication number Publication date
EP2303319B1 (en) 2016-10-05
EP2303319A2 (en) 2011-04-06
US20200345837A1 (en) 2020-11-05
US20220370602A1 (en) 2022-11-24
CN102123732A (zh) 2011-07-13
US10632190B2 (en) 2020-04-28
US11389530B2 (en) 2022-07-19
EP3156069B1 (en) 2020-08-05
US9764026B2 (en) 2017-09-19
US11351248B2 (en) 2022-06-07
AU2009259923A1 (en) 2009-12-23
US20220387582A1 (en) 2022-12-08
CA2728739A1 (en) 2009-12-23
CA2728739C (en) 2017-07-11
US20220378906A1 (en) 2022-12-01
US20150335732A1 (en) 2015-11-26
EP4218806A1 (en) 2023-08-02
US11376322B2 (en) 2022-07-05
JP6342982B2 (ja) 2018-06-13
WO2009155535A2 (en) 2009-12-23
AU2009259923B2 (en) 2015-09-03
EP3766517A1 (en) 2021-01-20
EP2303319A4 (en) 2012-09-26
JP2015134767A (ja) 2015-07-27
DK3156069T3 (da) 2020-09-21
US20120288473A1 (en) 2012-11-15
EP3156069B8 (en) 2020-10-21
WO2009155535A3 (en) 2010-04-22
US20200246452A1 (en) 2020-08-06
EP3766517B1 (en) 2022-11-02
US20220401552A1 (en) 2022-12-22
US11364295B2 (en) 2022-06-21
EP3156069A1 (en) 2017-04-19
US20180153982A1 (en) 2018-06-07
US12070496B2 (en) 2024-08-27
US20210000943A1 (en) 2021-01-07
US20210000944A1 (en) 2021-01-07
US20130189224A1 (en) 2013-07-25
JP2017081960A (ja) 2017-05-18
US9011835B2 (en) 2015-04-21
US8425898B2 (en) 2013-04-23

Similar Documents

Publication Publication Date Title
US12070496B2 (en) Compositions, methods and kits for eliciting an immune response
US9950056B2 (en) Compositions, methods and kits for eliciting an immune response
JP2021138721A (ja) Ｈｉｖ予備免疫化および免疫療法
JP2011526923A (ja) 免疫応答を誘起するための組成物および方法
HK40059969A (en) Compositions, methods and kits for eliciting an immune response
US12061186B2 (en) Compositions and methods for using cross-dressing to enhance anti-tumor immune responses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140226

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140324

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141001